All included treatments result ed in ADHD improvement .
On the basis of this literature review , a consistent pattern of improvement in pediatric ADHD patients ' core symptoms emerged across studies , study design s , and recommended treatment approaches .
OBJECTIVE The 2011 American Academy of Pediatrics attention-deficit/hyperactivity disorder ( ADHD ) guideline emphasizes monitoring and measuring outcomes of children diagnosed with ADHD ; however , recommendations for how to measure improvement are less clear .
A long-term goal was to develop an outcome measure that assesses the quality of care for children with ADHD .
As a first step in that process , we conducted a literature synthesis on the efficacy and effectiveness of guideline -recommended ADHD treatments on patient outcomes .
Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
OBJECTIVE The efficacy and safety of dexmethylpheni date extended release ( d-MPH-ER ) was compared to placebo in pediatric patients with attention-deficit/hyperactivity disorder ( ADHD ) . METHOD This multicenter , r and omized , double-blind , placebo-controlled , parallel-group , two-phase study included 97 patients ( ages 6 - 17 years ) with DSM-IV-defined ADHD . The study was carried out between 2001 and 2003 . After a 2-week evaluation phase , patients were r and omized to d-MPH-ER or placebo for 7 weeks . Flexible d-MPH-ER dosing ( 30 mg/day ) was permitted for 5 weeks , then patients remained on their optimal dose during the last 2 study weeks . The primary efficacy measure was change from baseline to final rating in Conners ADHD/DSM-IV Scale-Teacher version ( CADS-T ) total subscale score . Secondary efficacy variables included changes from baseline to final visit in CADS-T Inattentive and Hyperactive-Impulsive subscale scores , CADS-P DSM-IV total subscale score and Inattentive and Hyperactive-Impulsive subscale scores , Clinical Global Impressions-Improvement ( CGI-I ) and CGI-Severity ( CGI-S ) scale scores , and Child Health Question naire Parent Form 50 scores . RESULTS d-MPH-ER improved CADS-T total scores significantly compared with placebo ( p < .001 ) , and 67.3 % of d-MPH-ER patients were rated much improved or very much improved on CGI-I at final visit versus 13.3 % of placebo patients ( p < .001 ) . More patients taking d-MPH-ER ( 49.1 % ) than placebo ( 25.5 % ) spontaneously reported adverse events suspected as drug related . CONCLUSIONS Once-daily d-MPH-ER was more effective than placebo in the treatment of ADHD in children and adolescents
All included treatments result ed in ADHD improvement .
On the basis of this literature review , a consistent pattern of improvement in pediatric ADHD patients ' core symptoms emerged across studies , study design s , and recommended treatment approaches .
OBJECTIVE The 2011 American Academy of Pediatrics attention-deficit/hyperactivity disorder ( ADHD ) guideline emphasizes monitoring and measuring outcomes of children diagnosed with ADHD ; however , recommendations for how to measure improvement are less clear .
A long-term goal was to develop an outcome measure that assesses the quality of care for children with ADHD .
As a first step in that process , we conducted a literature synthesis on the efficacy and effectiveness of guideline -recommended ADHD treatments on patient outcomes .